This article was originally published in The Gray Sheet
Waiting period under the Hart-Scott-Rodino Act for the $2.1 bil. cash acquisition of Pfizer's Schneider unit by Boston Scientific expires on July 31, Pfizer reports ("The Gray Sheet" June 22, p. 2). For the three months ended June 30, Boston Scientific reports net income of $79 mil. compared to $90 mil. in the second quarter of 1997 (exclusive of special charges). Revenues are up 7% during the period to $506 mil
You may also be interested in...
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.